All Stories

  1. Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results

    Article • Journal of Neuropsychiatry, January 2023, American Psychiatric Association

    James Rucker

  2. Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)

    Article • Journal of Psychopharmacology, June 2022, SAGE Publications

    James Rucker

  3. Postpartum depression: A role for psychedelics?

    Article • Journal of Psychopharmacology, May 2022, SAGE Publications

    James Rucker

  4. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

    Article • Journal of Psychopharmacology, April 2022, SAGE Publications

    James Rucker

  5. An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry

    Article • Cannabis and Cannabinoid Research, January 2022, Mary Ann Liebert Inc

    James Rucker

  6. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder

    Article • Expert Review of Clinical Pharmacology, January 2022, Taylor & Francis

    James Rucker

  7. UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes

    Article • Journal of Cannabis Research, January 2022, Springer Science + Business Media

    James Rucker

  8. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

    Article • Journal of Psychopharmacology, January 2022, SAGE Publications

    James Rucker

  9. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

    Article • Expert Review of Clinical Pharmacology, December 2021, Taylor & Francis

    James Rucker

  10. Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

    Article • BMJ Open, December 2021, BMJ

    James Rucker

  11. A narrative synthesis of research with 5-MeO-DMT

    Article • Journal of Psychopharmacology, October 2021, SAGE Publications

    James Rucker

  12. Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry

    Article • The Journal of Clinical Pharmacology, October 2021, Wiley

    James Rucker

  13. International online survey of 1048 individuals with functional neurological disorder

    Article • European Journal of Neurology, August 2021, Wiley

    James Rucker

  14. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

    Article • CNS Drugs, July 2021, Springer Science + Business Media

    James Rucker

  15. Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

    Article • Frontiers in Psychiatry, June 2021, Frontiers

    James Rucker

  16. An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients

    Article • Neuropsychopharmacology Reports, May 2021, Wiley

    James Rucker

  17. Psilocybin: From Serendipity to Credibility?

    Article • Frontiers in Psychiatry, April 2021, Frontiers

    James Rucker

  18. Psilocybin and MDMA for the treatment of trauma-related psychopathology

    Article • International Review of Psychiatry, April 2021, Taylor & Francis

    James Rucker

  19. Psychedelics: Old drugs, new trips

    Article • Journal of Psychopharmacology, April 2021, SAGE Publications

    James Rucker

  20. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Article • Translational Psychiatry, March 2021, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  21. Effects of copy number variations on brain structure and risk for psychiatric illness: Large‐scale studies from the ENIGMA working groups on CNVs

    Article • Human Brain Mapping, February 2021, Wiley

    James Rucker

  22. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Article • January 2021, Center for Open Science

    James Rucker

  23. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA Working Groups on CNVs

    Article • January 2021, Center for Open Science

    James Rucker

  24. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

    Article • Journal of Psychopharmacology, December 2020, SAGE Publications

    James Rucker

  25. 20 International online survey of 1162 individuals with functional neurological disorder: demographics, symptom comorbidities, self- management strategies, and illness beliefs

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2020, BMJ

    James Rucker

  26. Historic psychedelic drug trials and the treatment of anxiety disorders

    Article • Depression and Anxiety, July 2020, Wiley

    James Rucker

  27. Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition

    Article • JAMA Psychiatry, April 2020, American Medical Association (AMA)

    James Rucker, Greig de Zubicaray

  28. Psychedelic treatment of functional neurological disorder: a systematic review

    Article • Therapeutic Advances in Psychopharmacology, January 2020, SAGE Publications

    James Rucker

  29. Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts

    Article • Biological Psychiatry, June 2019, Elsevier

    James Rucker

  30. Correction: Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

    Article • Molecular Psychiatry, January 2019, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  31. Psychiatry & the psychedelic drugs. Past, present & future

    Article • Neuropharmacology, November 2018, Elsevier

    James Rucker

  32. Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

    Article • Molecular Psychiatry, October 2018, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  33. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

    Article • Psychopharmacology, November 2017, Springer Science + Business Media

    James Rucker

  34. Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals

    Article • The British Journal of Psychiatry, August 2017, Cambridge University Press

    James Rucker

  35. Psychedelics in the treatment of unipolar mood disorders: a systematic review

    Article • Journal of Psychopharmacology, November 2016, SAGE Publications

    James Rucker

  36. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

    Article • The Lancet Psychiatry, July 2016, Elsevier

    James Rucker

  37. Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder

    Article • Biological Psychiatry, February 2016, Elsevier

    James Rucker

  38. A comparison of mental state examination documentation by junior clinicians in electronic health records before and after the introduction of a semi-structured assessment template (OPCRIT+)

    Article • International Journal of Medical Informatics, September 2015, Elsevier

    Matthew Hotopf, James Rucker

  39. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

    Article • BMJ, May 2015, BMJ

    James Rucker

  40. Chipping away at major depressive disorder

    Article • July 2014, Springer Science + Business Media

    James Rucker

  41. Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes

    Article • American Journal of Medical Genetics Part B Neuropsychiatric Genetics, April 2014, Wiley

    James Rucker

  42. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder

    Article • The Pharmacogenomics Journal, January 2014, Springer Science + Business Media

    James Rucker

  43. Correction: Harnessing Clinical Psychiatric Data with an Electronic Assessment Tool (OPCRIT+): The Utility of Symptom Dimensions

    Article • PLoS ONE, September 2013, PLOS

    Matthew Hotopf, James Rucker

  44. A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients

    Article • International Journal of Methods in Psychiatric Research, May 2013, Wiley

    James Rucker

  45. Male-Biased Autosomal Effect of 16p13.11 Copy Number Variation in Neurodevelopmental Disorders

    Article • PLoS ONE, April 2013, PLOS

    James Rucker

  46. Harnessing Clinical Psychiatric Data with an Electronic Assessment Tool (OPCRIT+): The Utility of Symptom Dimensions

    Article • PLoS ONE, March 2013, PLOS

    Matthew Hotopf, David O'Flynn, James Rucker

  47. Genomic structural variation in psychiatric disorders

    Article • Development and Psychopathology, October 2012, Cambridge University Press

    James Rucker

  48. Genome-wide association analysis of copy number variation in recurrent depressive disorder

    Article • Molecular Psychiatry, November 2011, Springer Science + Business Media

    James Rucker

  49. OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings

    Article • The British Journal of Psychiatry, August 2011, Royal College of Psychiatrists

    James Rucker

  50. Depressive disorder moderates the effect of the FTO gene on body mass index

    Article • Molecular Psychiatry, April 2011, Springer Science + Business Media

    James Rucker

  51. Polygenic Heterogeneity: A Complex Model of Genetic Inheritance in Psychiatric Disorders

    Article • Biological Psychiatry, August 2010, Elsevier

    James Rucker

  52. Mental capacity and psychiatric in-patients: implications for the new mental health law in England and Wales

    Article • The British Journal of Psychiatry, August 2009, Royal College of Psychiatrists

    James Rucker

  53. A Case of Prolonged Seizure After ECT in a Patient Treated With Clomipramine, Lithium, L-Tryptophan, Quetiapine, and Thyroxine for Major Depression

    Article • Journal of Ect, December 2008, Wolters Kluwer Health

    James Rucker

  54. Why do we need to understand the molecular basis of depression?

    Article • Biomarkers in Medicine, April 2008, Future Medicine

    James Rucker